Basics Lyell Immunopharma, Inc. IPO Date: June 17, 2021 Sector: Healthcare Industry: Biotech Market Cap: $121.6M Activated in VL: True Average Daily Range Avg Daily Range: $0.18 | 4.14% Avg Daily Range (30 D): $0.01 | 2.86% Avg Daily Range (90 D): $0.02 | 4.05% Institutional Daily Volume Avg Daily Volume: .74M Avg Daily Volume (30 D): .49M Avg Daily Volume (90 D): .7M Trade Size Avg Trade Size (Sh.): 127 Avg Trade Size (Sh.) (30 D): 215 Avg Trade Size (Sh.) (90 D): 243 Institutional Trades Total Inst.Trades: 337 Avg Inst. Trade: $1.97M Avg Inst. Trade (30 D): $1.86M Avg Inst. Trade (90 D): $1.86M Avg Inst. Trade Volume: .41M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.29M Avg Closing Trade (30 D): $.66M Avg Closing Trade (90 D): $.66M Avg Closing Volume: 489.5K         News May 1, 2025 @ 1:00 PM Lyell Immunopharma Announces Oral Presentation of ... Source: Lyell Immunopharma, Inc. Oct 24, 2024 @ 8:00 PM Lyell Immunopharma to Acquire ImmPACT Bio and Prio... Source: Globe Newswire Oct 4, 2024 @ 1:00 PM Lyell Immunopharma Announces the Acceptance Abstra... Source: N/A Jul 8, 2024 @ 5:02 PM Advanced Melanoma Clinical Trial Pipeline Analysis... Source: Delveinsight Jun 26, 2024 @ 11:00 AM Lyell Immunopharma Reports Dose-dependent Clinical... Source: Lyell Immunopharma, Inc Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.25 $-.18 $-.72 Diluted EPS $-1.25 $-.18 $-.72 Revenue $ .07M $ .01M $ .01M Gross Profit $ $ $ Net Income / Loss $ -334.52M $ -52.2M $ -191.94M Operating Income / Loss $ -360.55M $ -57.37M $ -201.15M Cost of Revenue $ $ $ Net Cash Flow $ -3.92M $ 14.73M $ 6.7M PE Ratio